A5087929754- Food Allergy and Anaphylaxis Research
- Allergic Rhinitis and Sensitization
- Asthma and respiratory diseases
- Transgenic Plants and Applications
- Respiratory and Cough-Related Research
- Contact Dermatitis and Allergies
- Infant Health and Development
- Plant and Fungal Interactions Research
- Herbal Medicine Research Studies
- Viral gastroenteritis research and epidemiology
- Mast cells and histamine
- Plant Virus Research Studies
- Plant Reproductive Biology
- Enterobacteriaceae and Cronobacter Research
- Drug-Induced Adverse Reactions
- Respiratory viral infections research
Karolinska University Hospital
2020-2024
Karolinska Institutet
2014-2023
Stockholm South General Hospital
2014-2019
Sachs' Children and Youth Hospital
2014-2019
Peanut oral immunotherapy (pOIT) has showed good short-term outcomes, but allergic reactions may prevent effective up-dosing and is a major cause of stopping OIT. In placebo-controlled trials, omalizumab been shown to facilitate allergen increase tolerance peanut.We hypothesized that by combining with pOIT, monitor treatment effects basophil threshold sensitivity tests (CD-sens), peanut patients could safely initiate pOIT thereafter slowly withdraw omalizumab.This the 2nd part one-armed open...
Summary Background Treatment with omalizumab has shown a positive effect on food allergies, but no dosages are established. Basophil allergen threshold sensitivity ( CD ‐sens) can be used to objectively measure treatment efficacy and correlates the outcome of double‐blind placebo‐controlled challenge peanut. Objective To evaluate whether individualized monitored by ‐sens could an effective intervention for suppression allergic reactions Methods Severely peanut adolescents n = 23) were...
Summary Background IgE sensitization to hazelnut is common, especially in birch endemic areas. However, its clinical significance often needs be confirmed by a food challenge. Objective To evaluate the of antibodies components and basophil allergen threshold sensitivity ( CD ‐sens) hazelnut, relation double‐blind placebo‐controlled challenge DBPCFC ) children with suspected allergy. Methods Forty underwent . ‐sens as well Cor 1, 8, 9 14 were analysed. Serum tryptase was measured before,...
BackgroundThe prevalence of peanut allergy is about 2% and mostly lifelong. Studies oral immunotherapy (OIT) with (the daily intake an initially low then increasing dose peanut) often show problematic side effects, but there are indications better safety effect in younger children compared older adults.ObjectiveTo determine the effectiveness OIT a slow up-dosing strategy maintenance aged 1 to 3 years who were allergic peanut, through 1-year interim analysis.MethodIn randomized controlled...
Abstract Anti‐IgE treatments, such as omalizumab, have shown promising effects in allergy treatment. Our previous work has that individualized omalizumab treatment (OT) allows a safe initiation and rapid up‐dosing of peanut oral immunotherapy (OIT) peanut‐allergic adolescents. However, the broader immunological this OT are incompletely understood. In pilot study, we longitudinally followed total B‐ T‐cell immunity during OT, using flow cytometry, ELISpot ELISA. Peripheral blood mononuclear...
Mast cells are activated during allergic reactions, releasing inflammatory mediators that include tryptase. This process leads to the symptoms of an reaction. A transient increase in total level serum tryptase indicates mast cell activation, e.g. anaphylactic may help confirm and assess extent a systemic In current study, was measured at different time points; before, after double-blind placebo-controlled food challenge (DBPCFC) with hazelnut 40 suspected children aged 6-18 years. Total...
Peanut allergy is a common food and the main cause of anaphylaxis among children. oral immunotherapy (pOIT) can lead to desensitization, combined treatment with omalizumab may facilitate OIT initiation. Still, mechanisms tolerance are not well understood. We therefore investigated transcriptional changes using RNA-seq profiles during pOIT. Peanut-allergic adolescents (n=17, age 12-19 years) were included treated for 8 weeks followed by step‐wise increase daily peanut ingestion, subsequent...
Transcriptome changes during peanut oral immunotherapy and omalizumab treatmentTo the Editor,Peanut allergy is a common food main cause of anaphylaxis among children1. In recent years, has emerged as promising treatment for children with different IgE-mediated allergies, although safety issues must be considered2. The aim to induce tolerance or desensitization an allergen which otherwise causes allergic reaction. For this means ingesting in controlled manner gradually increasing dosages....